A Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Brea
A phase 2/3 trial of Trastuzumab brengitecan, Pertuzumab, Docetaxel in her2-positive breast cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., now recruiting.
Overview
A Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer is a phase 2/3 interventional study registered as NCT06891833 by Sichuan Baili Pharmaceutical Co., Ltd., with 985 participants planned, started 2025-06-05 and due to reach its primary completion in 2028-12. Interventions recorded: BL-M07D1, Pertuzumab, docetaxel, carboplatin, trastuzumab. Conditions listed: HER2-positive Breast Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or M
Shares Trastuzumab brengitecan, Pertuzumab, SystImmune / Sichuan Biokin, Docetaxel.
- TrialA Study of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel in Patients With Unresectable Locally Advanced or Metastatic HER2-positive
Shares Trastuzumab brengitecan, Pertuzumab, SystImmune / Sichuan Biokin, Docetaxel.
- TrialA Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast Cancer
Shares Pertuzumab, Docetaxel, Trastuzumab, Carboplatin.
- TrialA Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
Shares Pertuzumab, Docetaxel, Trastuzumab, Carboplatin.
- TrialA Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer
Shares Pertuzumab, Docetaxel, Trastuzumab, HER2-positive breast cancer.
- TrialA Study Comparing BL-M07D1 With T-DM1 in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer
Shares Trastuzumab brengitecan, SystImmune / Sichuan Biokin, HER2-positive breast cancer.
- TrialA Study of BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HER2-positive Breast Cancer With Residual Invasive Cancer After Neoadjuvant Therapy
Shares Trastuzumab brengitecan, SystImmune / Sichuan Biokin, HER2-positive breast cancer.
- TrialHER2CLIMB-05
Shares Pertuzumab, Trastuzumab, HER2-positive breast cancer.